Zoetis provides healthcare services for animals. As the world’s leading animal health company, they are driven by a singular purpose: to nurture our world and humankind by advancing care for animals. 

Manufacturing

Pharmaceutical

Veterinary & Pet

Zoetis

Rimma Driscoll is Executive Vice President and Head of Global Strategy, Commercial Development and Business Development for Zoetis, the world leader in animal health and a member of the Fortune 500.

In this role, she leads development of the company’s global business strategy to nurture the world and humankind by advancing care for animals. Her responsibilities include ensuring successful execution of commercial development and launch plans for the company’s diverse portfolio. She also uses her experience to deliver Zoetis’ growth strategy through external business development and integration activities that support the company’s innovation agenda.

Ms. Driscoll joined Zoetis in 2016 as Vice President of Business Development. Under her leadership, Zoetis has successfully completed key acquisitions and partnerships to accelerate the company’s geographic expansion and growth in areas such as diagnostics, precision animal health and genetics. In addition, she has partnered across the business to advance innovation and identify investment opportunities that complement and strengthen the company’s product portfolio in various therapeutic areas.

Rimma Driscoll

Jamie Brannan is Executive Vice President and President of International Operations and Aquaculture at Zoetis, the world leader in animal health. In this role, he’s responsible for commercial operations in over 120 international markets and the global aquaculture business. As a senior business leader in human and animal health for over a decade, Mr. Brannan has consistently demonstrated his ability to build diverse teams with the agility to adjust through fast, evolving business conditions across international markets.

Jamie Brannan

Catherine Knupp is the EVP & President R&D at [Zoetis](/org/zoetis). Catherine joined the company in January 2001 as Vice President and was promoted to their current role in December 2005. Prior to joining [Zoetis](/org/zoetis), they were with Pfizer Global Research & Development as Vice President from January 1987 to December 2001. Catherine started their career with [Bristol-Myers Squibb](/org/bristol-myers-squibb) as a Vice President from January 1987 to December 2001.

Dr. Knupp received their DVM from the University of Illinois at Urbana-Champaign and their MS in Veterinary Medicine and Toxicology from the same school. Catherine also holds a BS in Chemistry from [Western Illinois University](/org/western-illinois-university).

They work with Glenn David - EVP & Group President, International Operations, Aquaculture, BioDevices and Pet Insurance, Tim Bettington - EVP & President, U.S. Operations and Global Customer Experience, and Wetteny Joseph - EVP & Chief Financial Officer. Catherine Knupp reports to Kristin Peck, CEO.

Catherine Knupp

Kristin Peck was appointed Chief Executive Officer of [Zoetis](/org/zoetis) in January 2020. In this role, she leads the world’s leading animal health company, a Fortune 500 organization with approximately $6 billion in annual revenue and 10,000 employees worldwide. Ms. Peck is also a member of the [Zoetis](/org/zoetis) Board of Directors.

Prior to becoming CEO, Ms. Peck was executive vice president and group president, U.S. Operations, Business Development and Strategy at [Zoetis](/org/zoetis).  Ms. Peck helped usher [Zoetis](/org/zoetis) through its Initial Public Offering in 2013 and has been a driving force of change in many roles at the company including Global Manufacturing and Supply, Global Poultry, Global Diagnostics, Corporate Development, and New Product Marketing and Global Market Research.  

Before joining [Zoetis](/org/zoetis), Ms. Peck served as executive vice president, Worldwide Business Development and Innovation at [Pfizer](/org/pfizer) Inc. and as a member of [Pfizer](/org/pfizer)'s Executive Leadership Team. In this role, she was responsible for the evaluation of strategic alternatives for [Pfizer](/org/pfizer)'s Animal Health and Nutrition businesses – paving the way for a public animal health company and attractive investment opportunity.  

Kristin Peck

Heidi Chen was appointed executive vice president, general counsel and corporate secretary at [Zoetis](/org/zoetis) in October 2012. In this role, she is responsible for [Zoetis](/org/zoetis)' worldwide legal affairs, compliance and enterprise risk management. In 2020, Ms. Chen was also given responsibility for the company’s Human Health Diagnostics business. 

Prior to [Zoetis](/org/zoetis), Ms. Chen was a vice president and assistant general counsel, [Pfizer](/org/pfizer) Inc. and chief counsel, [Pfizer](/org/pfizer) Animal Health. She joined [Pfizer](/org/pfizer) in 1998 and held numerous legal positions of increasing responsibility, including lead counsel for [Pfizer](/org/pfizer)’s Established Products (generics) business.  

Before [Pfizer](/org/pfizer), Ms. Chen was in private practice at [Clifford Chance](/org/clifford-chance-llp) in intellectual property and at [Hughes Hubbard & Reed](/org/hughes-hubbard-reed-llp) in litigation. She serves on the board of AALDEF, the Asian American Legal Education and Defense Fund. In 2016, she received the Justice in Action Award from AALDEF for her commitment to diversity.

Heidi Chen

Glenn David is executive vice president and group president of [Zoetis](/org/zoetis), the world leader in animal health. In this role, he is responsible for overseeing [Zoetis](/org/zoetis)’ international operations, aquaculture business (PHARMAQ), Global BioDevices, and Pumpkin Pet Insurance.

As a business leader in animal health for a decade, Mr. David brings broad industry experience to running businesses and making investments that have driven [Zoetis](/org/zoetis)’ growth. As a member of the [Zoetis](/org/zoetis) Executive team since 2016, he has played a pivotal role in supporting the company’s recent product launches, scrutinizing new business opportunities, and investing in global expansion initiatives.

Mr. David previously served as the company’s Chief Financial Officer from 2016 until June 2021, leading a diverse global team of finance professionals across 45 markets. In that role, he had responsibility for financial planning, external reporting, investor relations, treasury, tax, global operations and the company’s business development efforts. During his tenure as CFO, the company maintained a well-capitalized and financially disciplined business, creating significant value for shareholders.

Earlier in his career, Mr. David served as senior vice president of Finance Operations for [Zoetis](/org/zoetis) during its Initial Public Offering in 2013. From April 2014 through August 2014, Mr. David served as acting Chief Financial Officer of [Zoetis](/org/zoetis), overseeing financial management, reporting and shareholder relations and global procurement and operations.

Before the [Zoetis](/org/zoetis) IPO, Mr. David served in various financial roles at [Pfizer](/org/pfizer), including vice president of Global Finance for [Pfizer](/org/pfizer) Animal Health and vice president of Finance for the U.S. Primary Care franchise. Mr. David also played important financial roles in [Pfizer](/org/pfizer)’s integration of the Pharmacia, Wyeth and King Pharmaceuticals’ acquisitions. Prior to joining [Pfizer](/org/pfizer) in 1999, Mr. David gained valuable financial experience at Bankers Trust, Paine Webber and Credit Suisse.

Mr. David graduated magna cum laude with a bachelor’s degree in Finance from Binghamton University, and earned his MBA in Finance/Information Technology from New York University.

Glenn David

Roxanne Lagano was appointed executive vice president and chief human resources officer at [Zoetis](/org/zoetis) in November 2012. In this role, she is responsible for the company's worldwide human resources management and policies, colleague experience and award-winning workplace.

Ms. Lagano was given responsibility for the Global Operations and Security functions in 2020, and previously had oversight for the company’s Corporate Communications function from 2015-2019.

Prior to joining [Zoetis](/org/zoetis), Ms. Lagano was senior vice president, Global Compensation, Benefits and Wellness for [Pfizer](/org/pfizer). In that role, Ms. Lagano was responsible for the design and implementation of [Pfizer](/org/pfizer)'s compensation and employee benefit programs around the globe. She was also responsible for [Pfizer](/org/pfizer)'s wellness strategies, including the Healthy [Pfizer](/org/pfizer) program, and for the human resources aspects of the company's merger, acquisition and divestiture activities.

Roxanne Lagano

Nick Ashton is executive vice president and president, Global Manufacturing and Supply at [Zoetis](/org/zoetis). In this role, he oversees the company’s network of approximately 30 [Zoetis](/org/zoetis) manufacturing sites and 200 third-party manufacturers around the world.

Mr. Ashton joined [Zoetis](/org/zoetis) in 2020 as Head of Global External Supply, where he led all aspects of the company’s global external manufacturing network, overseeing 140 Contract Manufacturing Organizations (CMOs) to keep pace with customer demand. Mr. Ashton brings more than 25 years of global experience in areas of production, supply chain, external manufacturing, procurement, network strategy and execution for major international companies including GSK, Babcock International and Merck.

Mr. Ashton earned his bachelor’s degree in Chemical Engineering with Biochemical Engineering from Birmingham University.

Nick Ashton

Wetteny Joseph is executive vice president and Chief Financial Officer of [Zoetis](/org/zoetis), the world leader in animal health. In this role, he is responsible for overseeing the financial management, planning, operations and business development initiatives for this nearly $7 billion company. During his career, he has worked across diverse and complex businesses, leading finance functions and business units, and managing relationships with stakeholders from customers to investors.

Mr. Joseph joined [Zoetis](/org/zoetis) in June 2021, after having spent 13 years in executive positions at [Catalent](/org/catalent), a global leader in pharmaceuticals, biologics and consumer health products. Before joining [Zoetis](/org/zoetis), he was senior vice president and Chief Financial Officer of [Catalent](/org/catalent) for three years, overseeing accelerated financial growth and value creation at the company through transformational acquisitions and organic capital deployment. He first joined [Catalent](/org/catalent) in 2008 as vice president and corporate controller and held senior finance positions until October 2015, when he was named president of the Clinical Supply Services business, responsible for $400 million in annual sales from the global business unit.

Before joining [Catalent](/org/catalent), Mr. Joseph held a variety of senior financial positions at the industrial distribution company [HD Supply](/org/hd-supply-holdings-inc), including as CFO of its $1.2 billion plumbing and HVAC business unit. He also served as corporate controller for [Hughes Supply](/org/hughes-supply-inc), a Fortune 500, NYSE-listed company that was acquired by Home Depot and became part of [HD Supply](/org/hd-supply-holdings-inc). In his early career, Mr. Joseph spent six years at PricewaterhouseCoopers as an auditor and strategic financial advisor across a variety of industries.

Mr. Joseph holds both master’s and bachelor’s degrees in accounting from [Florida Atlantic University](/org/florida-atlantic-university) and is a Certified Public Accountant. Mr. Joseph is a member of the Executive Leadership Council (ELC) and a non-executive board member of Ashland Global (ASH).

Wetteny Joseph

Jeannette Ferran Astorga is Executive Vice President, Corporate Affairs, Communications and Sustainability, and Chief Sustainability Officer. She also serves as President of the Zoetis Foundation. In these roles, Ms. Ferran Astorga is responsible for the company’s integrated and comprehensive approach to public policy, social responsibility, corporate reputation, and colleague and leadership communications and leads the sustainability and ESG disclosure strategy. She joined Zoetis in September 2020 as the company’s first Head of Sustainability and has advised Zoetis leadership and Board of Directors on environmental, social and governance (ESG) and sustainability, launched the company’s long-range goals in the areas of environment and social impact, established the Zoetis Foundation, and led Zoetis’ first sustainability reporting to share progress toward its commitments.

Prior to joining Zoetis, Ms. Ferran Astorga was Vice President of Corporate Responsibility at the ascena Retail Group, where she led the global team responsible for supply chain compliance and sustainability, diversity and inclusion, and corporate philanthropy. Throughout her tenure in fashion retail, she held a variety of management roles with increasing responsibilities in information systems, merchandise planning and various business support functions.

Ms. Ferran Astorga was recognized as one of Assent’s 2020 Top 100 Corporate Social Responsibility Influence Leaders. Deeply committed to supporting women’s initiatives, she volunteers as a career counselor and executive mentor through various organizations including 92Y Women inPower and New Women, New Yorkers, a non-profit providing mentorship for immigrant women seeking employment in New York City.  She also is a member of the Board of Industry Advisors for LIM College in New York.

She earned a Bachelor of Science degree in International Marketing/Finance from Fordham University in New York and has completed a Harvard Business School Executive Education Program in Corporate Social Responsibility.

Jeannette Ferran Astorga

Robert J. Polzer, Ph.D., is Executive Vice President and President, Research and Development at Zoetis. In this role, he is responsible for leading a global organization that discovers, develops and registers new products, including genetic testing, vaccines, diagnostics and therapeutics that help predict, prevent, detect and treat animal health conditions in the eight core species that Zoetis serves. He also leads teams that develop new sensor and biodevice instruments to complement the core portfolio.

Dr. Polzer joined Zoetis in 2015 as the Head of Global Therapeutics where he led research and development activities to discover and register innovative solutions. He has been pivotal in advancing the company’s recent innovations, including monoclonal antibody platforms across species and therapeutic areas and a growing portfolio of companion animal parasiticides. He has also fostered external innovation collaborations with Colorado State University, which is developing new immunotherapies that could pave the way for alternatives to antibiotics in food-producing animals, and Regeneron, which is exploring the connections between animal and human health.

Prior to joining Zoetis, he spent over 20 years with Pfizer in drug metabolism research with roles of increasing organizational impact including global leadership of Pharmacokinetics, Dynamics, and Metabolism. He has a bachelor’s degree in Chemistry and German Literature from Muhlenberg College and earned his Ph.D. in Medicinal Chemistry at Purdue University.

Robert J. Polzer

Antoinette (Tonie) Leatherberry has served as a member of the Zoetis Board since December 2020.

Ms. Leatherberry retired from Deloitte, an industry-leading consulting, audit, tax and advisory services company, in 2020 after culminating a career of working with Fortune 500 companies on complex information technology transformations and operational issues. She has authored numerous articles and publications on information technology and governance, and was named to the National Association of Corporate Directors NACD Directorship 100 in 2019 and 2020.

Ms. Leatherberry has been recognized in such publications as Consulting Magazine’s Top 25 Consultants and Black Enterprise’s Most Powerful Women in Business.  

She has also devoted much of her professional life to creating opportunities for women and people of color. At Deloitte, Ms. Leatherberry was the principal architect of The Board Leadership Forum and the NextGen CEO Academy, which helped place more than 70 Black leaders into executive level and board roles. She currently serves as chair of the Executive Leadership Council (ELC), a preeminent association of Black business leaders, which focuses on board and executive leadership development, philanthropy, skills and talent development.  

Ms. Leatherberry serves on the Board of Directors for the American Family Insurance Mutual Holding Company, the Widener University Board of Trustees, and the Boston University Board of Trustees. She holds a bachelor’s degree in Mechanical Engineering from Boston University and an MBA in Operations Management and Supervision from Northeastern University, and is pursuing a doctorate in higher education policy at Widener University.

Antoinette Leatherberry

Sanjay Khosla

Louise M. Parent

Robert Scully

Willie M. Reed

Gregory Norden

Frank D’Amelio

Paul M. Bisaro

Linda Rhodes

Michael McCallister has served as Non-Executive Chairman of the [Zoetis](/org/zoetis) Board of Directors since June 2013 and as a member of our board since January 2013. Mr. McCallister served as Chairman of the Board of Humana from 2010 to 2013, where he presided over all meetings of the company’s stockholders as well as those for its Board of Directors and led the Board’s Corporate Governance efforts. 

Mr. McCallister was Chief Executive Officer for Humana from February 2000 until his retirement on December 31, 2012. During his tenure as CEO, Humana gained a reputation as one of the industry’s leading people-focused innovative companies, leveraging products, processes and technology to help individuals take control of their own health.

Beyond Humana, Mr. McCallister plays a leadership role in key business and community organizations. He served for many years on the board of the Business Roundtable and is past chairman of the organization’s Health and Retirement Task Force. He is currently on the boards of [AT&T](/org/att) and [Fifth Third Bank](/org/fifth-third-bank).

Mr. McCallister holds an MBA degree from [Pepperdine University](/org/pepperdine-university) in Malibu, CA.

Zoetis

Org chart

Teams

CEO and Executive Team

Leadership Team

Board of Directors

Discover similar companies